Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA

Authors:

Abstract
No abstract available
Funding Information
  • AbbVie

This publication has 29 references indexed in Scilit: